NEW YORK (GenomeWeb News) – Enzo Biochem reported after the close of the market Tuesday that its second quarter revenues increased 3 percent year over year, with growth posted for both its life sciences products and clinical lab services.

The New York-based diagnostics firm brought in total revenues of $22.9 million for the three months ended Jan. 31, up from $22.2 million for the second quarter of 2013.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.